TWI562994B - Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof - Google Patents

Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof

Info

Publication number: TWI562994B
Authority: TW; Taiwan
Prior art keywords: fgfr; preparation; therapeutic use; fgf receptor; dimeric compounds
Prior art date: 2011-12-28

Application number

TW101150736A

Other languages

English (en)

Other versions

TW201333006A (zh

Inventor

Marie-Line Clary-Ceccato

Nathalie Guillo

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-28

Filing date

2012-12-27

Publication date

2016-12-21

2012-12-27 Application filed by Sanofi Sa filed Critical Sanofi Sa

2013-08-16 Publication of TW201333006A publication Critical patent/TW201333006A/zh

2016-12-21 Application granted granted Critical

2016-12-21 Publication of TWI562994B publication Critical patent/TWI562994B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Neurology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

TW101150736A 2011-12-28 2012-12-27 Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof TWI562994B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1162485A FR2985257B1 (fr)	2011-12-28	2011-12-28	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique

Publications (2)

Publication Number	Publication Date
TW201333006A TW201333006A (zh)	2013-08-16
TWI562994B true TWI562994B (en)	2016-12-21

Family

ID=47716121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW101150736A TWI562994B (en)	2011-12-28	2012-12-27	Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof

Country Status (27)

Country	Link
US (1)	US9034898B2 (zh)
EP (1)	EP2797917B1 (zh)
JP (1)	JP6049756B2 (zh)
KR (1)	KR20140105578A (zh)
CN (1)	CN104136434B (zh)
AR (1)	AR089452A1 (zh)
AU (1)	AU2012360095B2 (zh)
BR (1)	BR112014015882A8 (zh)
CA (1)	CA2861718C (zh)
CY (1)	CY1119301T1 (zh)
DK (1)	DK2797917T3 (zh)
ES (1)	ES2602798T3 (zh)
FR (1)	FR2985257B1 (zh)
HK (1)	HK1198649A1 (zh)
HR (1)	HRP20161463T1 (zh)
HU (1)	HUE029515T2 (zh)
IL (1)	IL233324A (zh)
LT (1)	LT2797917T (zh)
MX (1)	MX356656B (zh)
PL (1)	PL2797917T3 (zh)
PT (1)	PT2797917T (zh)
RU (1)	RU2014131065A (zh)
SG (1)	SG11201403572RA (zh)
SI (1)	SI2797917T1 (zh)
TW (1)	TWI562994B (zh)
UY (1)	UY34561A (zh)
WO (1)	WO2013098764A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
BR112014030812B1 (pt)	2012-06-13	2022-11-08	Incyte Holdings Corporation	Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr
CN109627239B (zh)	2012-07-11	2021-10-12	缆图药品公司	成纤维细胞生长因子受体的抑制剂
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
ME03015B (me)	2013-04-19	2018-10-20	Incyte Holdings Corp	Biciklični heterocikli kao fgfr inhibitori
WO2014200682A1 (en) *	2013-05-24	2014-12-18	The Scripps Research Institute	Bidentate-binding modulators of lrrk2 and jnk kinases
PH12016500739B1 (en)	2013-10-25	2022-04-29	Blueprint Medicines Corp	Inhibitors of the fibrolast growth factor receptor
US9695165B2 (en)	2014-01-15	2017-07-04	Blueprint Medicines Corporation	Inhibitors of the fibroblast growth factor receptor
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CR20170390A (es)	2015-02-20	2017-10-23	Incyte Holdings Corp	Heterociclos biciclicos como inhibidores de fgfr
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3006897A1 (en)	2017-08-04	2019-02-04	University Health Network	Generation of oligodendrogenic neural progenitor cells
SG11202010636VA (en)	2018-05-04	2020-11-27	Incyte Corp	Solid forms of an fgfr inhibitor and processes for preparing the same
TW201946630A (zh)	2018-05-04	2019-12-16	美商英塞特公司	Fgfr抑制劑之鹽
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en)	2019-10-14	2024-10-10	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en)	2019-12-04	2022-06-02	Incyte Corporation	Derivatives of an FGFR inhibitor
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4323405A1 (en)	2021-04-12	2024-02-21	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
TW202313611A (zh)	2021-06-09	2023-04-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之三環雜環
CN113651810B (zh) *	2021-07-16	2023-10-13	上海毕得医药科技股份有限公司	一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007080325A1 (fr) *	2006-01-13	2007-07-19	Sanofi-Aventis	Composes dimeres agonistes des recepteurs des fgfs
WO2011023081A1 (en) *	2009-08-24	2011-03-03	Ascepion Pharmaceuticals, Inc.	5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
WO2011045344A1 (en) *	2009-10-13	2011-04-21	Pierre Fabre Medicament	Pyrazolopyridine derivatives as anticancer agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20010306A1 (es) *	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US20070066641A1 (en) *	2003-12-19	2007-03-22	Prabha Ibrahim	Compounds and methods for development of RET modulators
GB0402137D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
MX2010004260A (es) *	2007-10-16	2010-04-30	Wyeth Llc	Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa.
ES2652287T3 (es) *	2009-12-21	2018-02-01	Samumed, Llc	1H-pirazol [3,4-b] piridinas y usos terapéuticos de las mismas

2011
- 2011-12-28 FR FR1162485A patent/FR2985257B1/fr active Active
2012
- 2012-12-26 HU HUE12824734A patent/HUE029515T2/en unknown
- 2012-12-26 EP EP12824734.3A patent/EP2797917B1/en active Active
- 2012-12-26 KR KR1020147019813A patent/KR20140105578A/ko not_active Ceased
- 2012-12-26 WO PCT/IB2012/057727 patent/WO2013098764A1/en not_active Ceased
- 2012-12-26 HK HK14112113.1A patent/HK1198649A1/zh unknown
- 2012-12-26 AR ARP120104965A patent/AR089452A1/es unknown
- 2012-12-26 LT LTEP12824734.3T patent/LT2797917T/lt unknown
- 2012-12-26 RU RU2014131065A patent/RU2014131065A/ru not_active Application Discontinuation
- 2012-12-26 SI SI201230759A patent/SI2797917T1/sl unknown
- 2012-12-26 PT PT128247343T patent/PT2797917T/pt unknown
- 2012-12-26 HR HRP20161463TT patent/HRP20161463T1/hr unknown
- 2012-12-26 CN CN201280070640.9A patent/CN104136434B/zh active Active
- 2012-12-26 PL PL12824734T patent/PL2797917T3/pl unknown
- 2012-12-26 ES ES12824734.3T patent/ES2602798T3/es active Active
- 2012-12-26 DK DK12824734.3T patent/DK2797917T3/en active
- 2012-12-26 BR BR112014015882A patent/BR112014015882A8/pt not_active Application Discontinuation
- 2012-12-26 SG SG11201403572RA patent/SG11201403572RA/en unknown
- 2012-12-26 MX MX2014007843A patent/MX356656B/es active IP Right Grant
- 2012-12-26 JP JP2014549609A patent/JP6049756B2/ja active Active
- 2012-12-26 CA CA2861718A patent/CA2861718C/en not_active Expired - Fee Related
- 2012-12-26 AU AU2012360095A patent/AU2012360095B2/en not_active Ceased
- 2012-12-26 US US14/369,160 patent/US9034898B2/en active Active
- 2012-12-27 TW TW101150736A patent/TWI562994B/zh not_active IP Right Cessation
- 2012-12-28 UY UY0001034561A patent/UY34561A/es not_active Application Discontinuation
2014
- 2014-06-23 IL IL233324A patent/IL233324A/en not_active IP Right Cessation
2016
- 2016-11-09 CY CY20161101150T patent/CY1119301T1/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007080325A1 (fr) *	2006-01-13	2007-07-19	Sanofi-Aventis	Composes dimeres agonistes des recepteurs des fgfs
WO2011023081A1 (en) *	2009-08-24	2011-03-03	Ascepion Pharmaceuticals, Inc.	5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
WO2011045344A1 (en) *	2009-10-13	2011-04-21	Pierre Fabre Medicament	Pyrazolopyridine derivatives as anticancer agent

Also Published As

Publication number	Publication date
US20150011579A1 (en)	2015-01-08
ES2602798T3 (es)	2017-02-22
BR112014015882A8 (pt)	2017-07-04
CA2861718C (en)	2019-09-17
HUE029515T2 (en)	2017-02-28
JP2015503546A (ja)	2015-02-02
SI2797917T1 (sl)	2016-12-30
EP2797917A1 (en)	2014-11-05
FR2985257A1 (fr)	2013-07-05
CA2861718A1 (en)	2013-07-04
KR20140105578A (ko)	2014-09-01
AU2012360095A1 (en)	2014-07-24
WO2013098764A1 (en)	2013-07-04
JP6049756B2 (ja)	2016-12-21
AR089452A1 (es)	2014-08-27
HK1198649A1 (zh)	2015-05-22
US9034898B2 (en)	2015-05-19
MX2014007843A (es)	2014-11-25
AU2012360095B2 (en)	2017-02-02
TW201333006A (zh)	2013-08-16
EP2797917B1 (en)	2016-08-10
IL233324A (en)	2017-03-30
FR2985257B1 (fr)	2014-02-14
HRP20161463T1 (hr)	2016-12-16
PT2797917T (pt)	2016-11-15
PL2797917T3 (pl)	2017-08-31
CY1119301T1 (el)	2018-02-14
IL233324A0 (en)	2014-08-31
SG11201403572RA (en)	2014-07-30
MX356656B (es)	2018-06-07
UY34561A (es)	2013-07-31
DK2797917T3 (en)	2016-12-05
LT2797917T (lt)	2016-11-25
CN104136434B (zh)	2016-07-06
RU2014131065A (ru)	2016-02-20
BR112014015882A2 (pt)	2017-06-13
CN104136434A (zh)	2014-11-05

Publication	Publication Date	Title
TWI562994B (en)	2016-12-21	Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof
IL233325A0 (en)	2014-08-31	Dimeric compounds as an agonist for the fgfr (fgf) receptor, a process for their preparation and their therapeutic use
ZA201209632B (en)	2014-03-26	Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
PT2726141T (pt)	2020-02-24	Dispositivo para administração oral de compostos terapêuticos
TWI559916B (en)	2016-12-01	Medication supplying apparatus
ZA201300100B (en)	2014-03-26	Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
IL232906A (en)	2017-12-31	Pyrazolopyridine derivatives, a process for their preparation and medical use
PH12014500970A1 (en)	2014-06-09	Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
IL239146A0 (en)	2015-07-30	Aminocyclobutane derivatives, methods for their preparation and their use as drugs
ZA201309559B (en)	2014-08-27	Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof
IL227544B (en)	2018-08-30	(r)- Leoplomide, a method for its preparation and its medical uses
SMT201700528T1 (it)	2018-01-11	2-alchil-1-osso-n-fenil-3-eteroaril-1,2,3,4-tetraidroisochinolin-4-carbossammidi sostituite per le terapie antimalariche
PL395184A1 (pl)	2012-12-17	Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu
HK1179251A (zh)	2013-09-27	咪唑并吡啶衍生物、其制造方法及其治疗用途

Legal Events

Date	Code	Title	Description
2018-09-21	MM4A	Annulment or lapse of patent due to non-payment of fees